Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients

Reuters

2025/10/30

<a href="https://laohu8.com/S/TECX">Tectonic Therapeutic</a> Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients

Tectonic Therapeutic Inc. announced positive topline results from its Phase 1b Part B clinical trial evaluating TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF). The trial demonstrated that a single intravenous dose of TX45 was well tolerated and showed meaningful improvements in left heart function and pulmonary hemodynamics. No serious or severe adverse events, clinically significant changes in blood pressure, or immune-related reactions were reported. The company is also conducting the APEX Phase 2 trial of TX45 in patients with Group 2 pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), with topline results expected in 2026. The Phase 1b results were presented by the company on October 29, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564789-en) on October 29, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579138473"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579138473\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579138473?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579138473","market":"us","top_or_hot":-1,"title":"Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TECX\">Tectonic Therapeutic</a> Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tectonic Therapeutic Inc. announced positive topline results from its Phase 1b Part B clinical trial evaluating TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF). The trial demonstrated that a single intravenous dose of TX45 was well tolerated and showed meaningful improvements in left heart function and pulmonary hemodynamics. No serious or severe adverse events, clinically significant changes in blood pressure, or immune-related reactions were reported. The company is also conducting the APEX Phase 2 trial of TX45 in patients with Group 2 pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), with topline results expected in 2026. The Phase 1b results were presented by the company on October 29, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564789-en) on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTectonic Therapeutic Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-30 04:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TECX\">Tectonic Therapeutic</a> Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tectonic Therapeutic Inc. announced positive topline results from its Phase 1b Part B clinical trial evaluating TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF). The trial demonstrated that a single intravenous dose of TX45 was well tolerated and showed meaningful improvements in left heart function and pulmonary hemodynamics. No serious or severe adverse events, clinically significant changes in blood pressure, or immune-related reactions were reported. The company is also conducting the APEX Phase 2 trial of TX45 in patients with Group 2 pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), with topline results expected in 2026. The Phase 1b results were presented by the company on October 29, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564789-en) on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TECX","symbol_name":"Tectonic Therapeutic, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL9GFJbv:1","article_id":"2579138473","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579138473","pubTimestamp":1761768078,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tectonic Therapeutic Inc. announced positive topline results from its Phase 1b Part B clinical trial evaluating TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension in heart failure with reduced ejection fraction . The trial demonstrated that a single intravenous dose of TX45 was well tolerated and showed meaningful improvements in left heart function and pulmonary hemodynamics. No serious or severe adverse events, clinically significant changes in blood pressure, or immune-related reactions were reported. The company is also conducting the APEX Phase 2 trial of TX45 in patients with Group 2 pulmonary hypertension in heart failure with preserved ejection fraction , with topline results expected in 2026. The Phase 1b results were presented by the company on October 29, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TECX":"Tectonic Therapeutic, Inc.","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Tectonic Therapeutic报告TX45在PH-HFrEF患者中的阳性1b期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECX":0.9,"NDAQ":0.9},"content_text":"Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in PH-HFrEF Patients\n    \n\n        Tectonic Therapeutic Inc. announced positive topline results from its Phase 1b Part B clinical trial evaluating TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF). The trial demonstrated that a single intravenous dose of TX45 was well tolerated and showed meaningful improvements in left heart function and pulmonary hemodynamics. No serious or severe adverse events, clinically significant changes in blood pressure, or immune-related reactions were reported. The company is also conducting the APEX Phase 2 trial of TX45 in patients with Group 2 pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), with topline results expected in 2026. The Phase 1b results were presented by the company on October 29, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564789-en) on October 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}